Complications of Implantable Cardioverter Defibrillator and Their Potential Risk Factors in Patients with Hypertrophic Cardiomyopathy

被引:0
|
作者
Goudarzi, Mohammad Taghi Hedayati [1 ]
Moradi, Maryam [2 ]
Abrotan, Saeed [1 ]
Saravi, Mehrdad [2 ]
Shirafkan, Hoda [3 ]
Irilouzadian, Rana [4 ]
Omran, Hossein Salehi [1 ]
机构
[1] Babol Univ Med Sci, Rohani Hosp, Sch Med, Dept Cardiol, Babol, Iran
[2] Babol Univ Med Sci, Fac Med, Dept Cardiol, Babol, Iran
[3] Babol Univ Med Sci, Hlth Res Inst, Social Determinants Hlth Res Ctr, Babol, Iran
[4] Iran Univ Med Sci, Burn Res Ctr, Tehran, Iran
关键词
SUDDEN-DEATH; TASK-FORCE; THERAPY; POPULATION; PREVENTION; EFFICACY; OUTCOMES; SOCIETY;
D O I
10.1155/2023/4552100
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Hypertrophic cardiomyopathy (HCM) has different complications such as cardiac arrhythmia and sudden cardiac death (SCD). Insertion of an implantable cardioverter defibrillator (ICD) is recommended for HCM patients who are at high risk of SCD and malignant arrhythmias, despite having their own potential complications. Hypothesis. We aimed to investigate the prevalence of different complications of ICD insertion and the impact of the potential influential baseline characteristics in a one-year follow-up period. Methods. This was a retrospective study with a total of 71 HCM patients with ICD insertion. We evaluated the prevalence of different complications of ICD implantation and the impact of baseline characteristics on the occurrence of ICD complications using multivariate regression analysis in three 4-month periods. Results. In a one-year follow-up, 13 patients (18.3%) experienced at least one of the complications including pneumothorax, lead failure, ICD infection, inappropriate shocks, perforation, and upper limb deep vein thrombosis (DVT) with no mortality. Inappropriate shocks were reported as the most common (11.3%) complication during this period, with a gradual increase in the second (4.2%) and third (5.6%) follow-up sessions. Among all of the baseline characteristics that were investigated in this study, a positive history of hypertension was the only risk factor with significant impact on the occurrence of complications (P = 0.01). Conclusion. We demonstrated the occurrence of complications during a one-year follow-up as 18.3% in HCM patients with ICD insertion. A positive history of hypertension was the only baseline characteristic affecting the occurrence of complications, and inappropriate shocks were the most common complication.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] The survival, efficacy and complications of implantable cardioverter defibrillator therapy in patients with hypertrophic cardiomyopathy
    Vriesendorp, P. A.
    Schinkel, A. F. L.
    Theuns, D. A. M. J.
    Van Slegtenhorst, M. A.
    Wessels, M. W.
    Jordaens, L. J. L. M.
    Ten Cate, F. J.
    Michels, M.
    EUROPEAN HEART JOURNAL, 2012, 33 : 542 - 542
  • [2] Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy
    Lin, G.
    Nishimura, R. A.
    Gersh, B. J.
    Phil, D.
    Ommen, S. R.
    Ackerman, M. J.
    Brady, P. A.
    HEART, 2009, 95 (09) : 709 - 714
  • [3] Future risk of bradyarrhythmias in patients with hypertrophic cardiomyopathy and implantable cardioverter defibrillator indication
    Nakasuka, K.
    Kitada, S.
    Kawada, Y.
    Kato, M.
    Ohte, N.
    EUROPEAN HEART JOURNAL, 2019, 40 : 581 - 581
  • [4] Hypertrophic cardiomyopathy and the implantable cardioverter-defibrillator
    Manovel-Sanchez, Ana J.
    Pedrote-Martinez, Alonso
    Arana-Rueda, Eduardo
    de Tejada, Francisco Errazquin-Saenz
    REVISTA ESPANOLA DE CARDIOLOGIA, 2007, 60 (07): : 784 - 784
  • [5] Implantable cardioverter defibrillator in patients with hypertrophic cardiomyopathy - A nationwide study
    Amin, A.
    Tsangaris, A.
    Arora, A.
    Satya, K.
    EUROPEAN HEART JOURNAL, 2018, 39 : 54 - 55
  • [6] Prognosis of apical hypertrophic cardiomyopathy in patients with an implantable cardioverter defibrillator
    Nakano, M.
    Kondo, Y.
    Nakano, M.
    Kajiyama, T.
    Ito, R.
    Takahira, H.
    Kitagawa, M.
    Sugawara, M.
    Chiba, T.
    Kobayashi, Y.
    EUROPEAN HEART JOURNAL, 2021, 42 : 627 - 627
  • [7] Impact of implantable cardioverter defibrillator therapy in patients with hypertrophic cardiomyopathy
    Dias, L. C.
    Saad, E. B.
    Slater, C.
    Inacio, L. A. O., Jr.
    Santos, G. V.
    Camanho, L. E. M.
    Mourilhe-Rocha, R.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 6 - 6
  • [8] Prognosis of hypertrophic cardiomyopathy in Japanese patients with an implantable cardioverter defibrillator -focus on apical hypertrophic cardiomyopathy
    Nakano, M.
    Kondo, Y.
    Nakano, M.
    Kajiyama, T.
    Ito, R.
    Kitagawa, M.
    Sugawara, M.
    Chiba, T.
    Ryuzaki, S.
    Yoshino, Y.
    Kobayashi, Y.
    EUROPEAN HEART JOURNAL, 2022, 43 : 663 - 663
  • [9] The prevalence of internal cardioverter defibrillator complications in patients with hypertrophic cardiomyopathy
    O'mahony, C.
    Cardona, M.
    Quarta, G.
    Lambiase, P. D.
    Elliott, P.
    EUROPEAN HEART JOURNAL, 2010, 31 : 845 - 846
  • [10] Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy
    Francia, Pietro
    Adduci, Carmen
    Palano, Francesca
    Semprini, Lorenzo
    Serdoz, Andrea
    Montesanti, Dalma
    Santini, Daria
    Musumeci, Beatrice
    Salvati, Adriano
    Volpe, Massimo
    Autore, Camillo
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2015, 26 (08) : 893 - 899